» Articles » PMID: 33139767

Hepatobiliary Malignancies Have Distinct Peripheral Myeloid-derived Suppressor Cell Signatures and Tumor Myeloid Cell Profiles

Abstract

Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells that are increased in patients with numerous malignancies including viral-derived hepatocellular carcinoma (HCC). Here, we report an elevation of MDSCs in the peripheral blood of patients with other hepatobiliary malignancies including non-viral HCC, neuroendocrine tumors (NET), and colorectal carcinoma with liver metastases (CRLM), but not cholangiocarcinoma (CCA). The investigation of myeloid cell infiltration in HCC, NET and intrahepatic CCA tumors further established that the frequency of antigen-presenting cells was limited compared to benign lesions, suggesting that primary and metastatic hepatobiliary cancers have distinct peripheral and tumoral myeloid signatures. Bioinformatics analysis of The Cancer Genome Atlas dataset demonstrated that a high MDSC score in HCC patients is associated with poor disease outcome. Given our observation that MDSCs are increased in non-CCA malignant liver cancers, these cells may represent suitable targets for effective immunotherapy approaches.

Citing Articles

Genetic, Epigenetic, and Microenvironmental Drivers of Cholangiocarcinoma.

Putatunda V, Jusakul A, Roberts L, Wang X Am J Pathol. 2024; 195(3):362-377.

PMID: 39532242 PMC: 11841490. DOI: 10.1016/j.ajpath.2024.10.013.


Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications.

Ricci A, Rizzo A, Schirizzi A, DAlessandro R, Frega G, Brandi G Cancers (Basel). 2024; 16(20).

PMID: 39456636 PMC: 11505966. DOI: 10.3390/cancers16203542.


Immunotherapy for hepatocellular carcinoma.

Childs A, Aidoo-Micah G, Maini M, Meyer T JHEP Rep. 2024; 6(10):101130.

PMID: 39308986 PMC: 11414669. DOI: 10.1016/j.jhepr.2024.101130.


Pediatric Hepatocellular Adenomas: What Is Known and What Is New?.

Espinoza A, Vasudevan S, Masand P, Lopez-Terrada D, Patel K Cancers (Basel). 2023; 15(19).

PMID: 37835484 PMC: 10571754. DOI: 10.3390/cancers15194790.


Immunobiology of cholangiocarcinoma.

Tomlinson J, Valle J, Ilyas S J Hepatol. 2023; 79(3):867-875.

PMID: 37201670 PMC: 10524996. DOI: 10.1016/j.jhep.2023.05.010.


References
1.
Karin M . New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. Precis Clin Med. 2019; 1(1):21-28. PMC: 6333043. DOI: 10.1093/pcmedi/pby005. View

2.
Draghiciu O, Lubbers J, Nijman H, Daemen T . Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology. 2015; 4(1):e954829. PMC: 4368153. DOI: 10.4161/21624011.2014.954829. View

3.
Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside T . Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods. 2012; 381(1-2):14-22. PMC: 3385927. DOI: 10.1016/j.jim.2012.04.004. View

4.
Youn J, Nagaraj S, Collazo M, Gabrilovich D . Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008; 181(8):5791-802. PMC: 2575748. DOI: 10.4049/jimmunol.181.8.5791. View

5.
Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P . Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Front Immunol. 2018; 9:398. PMC: 5840207. DOI: 10.3389/fimmu.2018.00398. View